An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 426-436

  Phapale, P B ^a,b   Kim, S D ^b   Lee, H W ^a,b   Lim, M ^a,b   Kale, D D ^a,b   Kim, Y L ^b   Cho, J H ^c   Hwang, D ^c   Yoon, Y R ^a,b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GENETIC VARIABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PARTIAL LEAST SQUARES REGRESSION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

ADMINISTRATION, ORAL; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEAST-SQUARES ANALYSIS; MALE; MASS SPECTROMETRY; METABOLOMICS; MODELS, BIOLOGICAL; PHENOTYPE; TACROLIMUS; YOUNG ADULT;

EID: 77949875295     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.296     Document Type: Article

References (49)

1. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
2. Li, H. et al. Pharmacometabonomic phenotyping reveals diferent responses to xenobiotic intervention in rats. J. Proteome Res. 6, 1364-1370 (2007).
3. Ebbels, T.M. et al. Prediction and classifcation of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6, 4407-4422 (2007).
4. Keun, H.C. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109, 92-106 (2006).
5. Vesell, E.S. Genetic and environmental factors causing variation in drug response. Mutat. Res. 247, 241-257 (1991).
6. Spear, B.B., Heath-Chiozzi, M. & Huf, J. Clinical application of pharmacogenetics. Trends. Mol. Med. 7, 201-204 (2001).
7. Pagliarulo, V., Datar, R.H. & Cote, R.J. Role of genetic and expression profling in pharmacogenomics: the changing face of patient management. Curr. Issues Mol. Biol. 4, 101-110 (2002).
8. Nebert, D.W., Jorge-Nebert, L. & Vesell, E.S. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am. J. Pharmacogenomics 3, 361-370 (2003).
9. Pusztai, L. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics 8, 1443-1448 (2007).
10. Nicholson, J.K. Omics dreams of personalized healthcare. J. Proteome Res. 5, 2067, 2069 (2006).
11. Nebert, D.W. & Vesell, E.S. Can personalized drug therapy be achieved? a closer look at pharmaco-metabonomics. Trends Pharmacol. Sci. 27, 580-586 (2006).
12. Schnackenberg, L.K. Global metabolic profling and its role in systems biology to advance personalized medicine in the 21st century. Expert Rev. Mol. Diagn. 7, 247-259 (2007).
13. Nicholson, J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2, 52 (2006).
14. Kaddurah-Daouk, R., Kristal, B.S. & Weinshilboum, R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653-683 (2008).
15. Nicholson, J.K., Connelly, J., Lindon, J.C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1, 153-161 (2002).
16. van der Greef, J., Hankemeier, T. & McBurney, R.N. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 7, 1087-1094 (2006).
17. Bernini, P. et al. Individual human phenotypes in metabolic space and time. J. Proteome Res. 8, 4264-4271 (2009).
18. Hwang, D., Stephanopoulos, G. & Chan, C. Inverse modeling using multi-block PLS to determine the environmental conditions that provide optimal cellular function. Bioinformatics 20, 487-499 (2004).
19. Chan, C., Hwang, D., Stephanopoulos, G.N., Yarmush, M.L. & Stephanopoulos, G. application of multivariate analysis to optimize function of cultured hepatocytes. Biotechnol. Prog. 19, 580-598 (2003).
20. Wold, S.,Trygg, J.,Berglund, A. & Antti, H. Some recent developments in PLS modeling. Chemometr. Intellig. Lab. Syst. 58, 131-150 (2001).
21. Venkataramanan, R. et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29, 404-430 (1995).
22. Holmes, E. et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400 (2008).
23. Sreekumar, a. et al. Metabolomic profles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914(2009).
24. Want, E.J., Nordström, A., Morita, H. & Siuzdak, G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res. 6, 459-468 (2007).
25. Theodoridisa, G.,Gika, H.G. & Wilson, I.D. LC-MS-based methodology for global metabolite profling in metabonomics/metabolomics. TrAC Trends Anal. Chem. 27, 251-260 (2008).
26. Smith, C.A., Want, E.J., O'Maille, G., abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profling using nonlinear peak alignment, matching, and identifcation. Anal. Chem. 78, 779-787 (2006)
27. Nordström, A., O'Maille, G., Qin, C. & Siuzdak, G. Nonlinear data alignment for UPLC-MS and HPLC-MS based metabolomics: quantitative analysis of endogenous and exogenous metabolites in human serum. Anal. Chem. 78, 3289-3295 (2006).
28. Bolstad, B.M., Irizarry, R.A., astrand, M. & Speed, T.P. a comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
29. Park, K., Kim, Y.S., Kwon, K.I., Park, M.S., Lee, Y.J. & Kim, K.H. a randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin. Ther. 29, 154-162 (2007).
30. Choi, J.H., Lee, Y.J., Jang, S.B., Lee, J.E., Kim, K.H. & Park, K. Infuence of the CYP3a5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br. J. Clin. Pharmacol. 64, 185-191 (2007)
31. Burnham, a.J.,MacGregor, J.F. & Viveros, R. Latent variable multivariate regression modeling. Chemometr. Intellig. Lab. Syst. 48, 167-180 (1999).
32. Mertens, B.,Fearn, T. & Thompson, M. The efcient cross-validation of principal components applied to principal component regression. Stat. Comput. 5, 227-235 (1995).
33. Lindgren, F.,Hansen, B.,Karcher, W.,Sjöström, M. & Eriksson, L. Model validation by permutation tests: applications to variable selection. J. Chemometr. 10, 521-532 (1998).
34. Wishart, D.S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521-D526 (2007).
35. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
36. Caspi, R. et al. The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res. 36, D623-D631 (2008).
37. Dufort, I., Soucy, P., Lacoste, L. & Luu-The, V. Comparative biosynthetic pathway of androstenol and androgens. J. Steroid Biochem. Mol. Biol. 77, 223-227 (2001)
38. Anglicheau, D. et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant. 18, 2409-2414 (2003).
39. El-Sankary, W., Plant, N.J., Gibson, G.G. & Moore, D.J. Regulation of the CYP3a4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab. Dispos. 28, 493-496 (2000).
40. Van Duijnhoven, E.M., Boots, J.M., Christiaans, M.H., Stolk, L.M., Undre, N.A. & van Hoof, J.P. Increase in tacrolimus trough levels after steroid withdrawal. Transpl. Int. 16, 721-725 (2003).
41. Chuang, H.Y., Lee, E., Liu, Y.T., Lee, D. & Ideker, T. Network-based classifcation of breast cancer metastasis. Mol. Syst. Biol. 3, 140 (2007).
42. Kalra, R., Singh, S.P., Pena-Philippides, J.C., Langley, R.J., Razani-Boroujerdi, S. & Sopori, M.L. Immunosuppressive and anti-infammatory efects of nicotine administered by patch in an animal model. Clin. Diagn. Lab. Immunol. 11, 563-568 (2004).
43. Wajner, M., Schlottfeldt, J.L., Ckless, K. & Wannmacher, C.M. Immunosuppressive efects of organic acids accumulating in patients with maple syrup urine disease. J. Inherit. Metab. Dis. 18, 165-168 (1995).
44. Mizuta, K., Kobayashi, E., Uchida, H., Fujimura, a., Kawarasaki, H. & Hashizume, K. Infuence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model. Comparative study with cyclosporine. Transpl. Int. 12, 316-322 (1999).
45. Morineau, G. et al. Convenient chromatographic prepurifcation step before measurement of urinary cortisol by radioimmunoassay. Clin. Chem. 43, 786-793 (1997).
46. Gundlach, G., Käbisch, A., Voegeli, R., Pralle, H. & Hartenfels, S. Determination of phosphoethanolamine in urine or in the presence of high taurine concentrations. Anal. Biochem. 142, 511-514 (1984).
47. Girish, B.,Chheda, A.M. & Grace, J.T. Jr. Nucleosides in human urine I: isolation and identifcation of N2-dimethylguanosine, 1-methylinosine, and N2-methylguanosine from normal human urine. J. Pharmaceut. Sci. 58, 75-78 (1968).
48. Chen, Y.L., Hirabayashi, H., Akhtar, S., Pelzer, M. & Kobayashi, M. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 330-341 (2006).
49. Gika, H.G., Theodoridis, G.a., Wingate, J.E. & Wilson, I.D. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6, 3291-3303 (2007).